To read the full story, subscribe or sign in.

Pfizer, Avir arrangements in hand, Basilea still hunts for additional tie-ups: CEO

June 16, 2017

After a spate of upbeat news, Basilea Pharmaceutica International Ltd. is not slowing down, CEO Ronald Scott said, and the company is “very active in talking to potential partners for our assets at all stages.”

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for March 27, 2026.

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...